Skip to main content

Table 3 Correlations between KMT2A gene rearrangement and immunological markers

From: Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children

Immunological markerKMT2A rearrangementKMT2A subgroups
Neg (%)Pos (%)PKMT2A-AFF1+ (%)Other KMT2A+ (%)P
CD2
 Neg83 (93)32 (100)0.13216 (100)16 (100)
 Pos6 (7)0 (0)0 (0)0 (0)
CD5
 Neg86 (97)32 (100)0.29316 (100)16 (100)
 Pos3 (3)0 (0)0 (0)0 (0)
CD7
 Neg86 (97)25 (78)0.00112 (75)13 (81)0.669
 Pos3 (3)7 (22)4 (25)3 (19)
CD20
 Neg78 (94)26 (94)0.99913 (100)13 (87)0.484
 Pos5 (6)2 (6)0 (0)2 (13)
CD22
 Neg16 (28)12 (75)0.0118 (73)4 (44)0.362
 Pos41 (72)8 (25)3 (27)5 (56)
CD56
 Neg46 (84)18 (86)0.9998 (80)10 (91)0.586
 Pos9 (16)3 (14)2 (20)1 (9)
CD58
 Neg45 (82)16 (76)0.5818 (80)8 (73)0.696
 Pos10 (18)5 (24)2 (20)3 (27)
CD13
 Neg65 (73)31 (97)0.00415 (94)16 (100)0.999
 Pos24 (27)1 (3)1 (6)0 (0)
CD33
 Neg34 (38)26 (81)<0.00115 (94)11 (69)0.172
 Pos55 (62)6 (19)1 (6)5 (31)
CD15
 Neg50 (91)10 (48)<0.0011 (10)9 (82)0.002
 Pos5 (9)11 (52)9 (90)2 (18)
CD66c
 Neg50 (91)21 (100)0.15310 (100)11 (100)
 Pos5 (9)0 (0)0 (0)0 (0)
CD34
 Neg9 (19)17 (53)<0.0016 (38)11 (69)0.077
 Pos80 (90)15 (47)10 (62)5 (31)
CD133
 Neg39 (71)9 (43)0.0231 (10)8 (73)0.008
 Pos16 (29)12 (57)9 (90)3 (27)
NG2
 Neg43 (78)3 (14)<0.0010 (0)3 (73)0.214
 Pos12 (22)18 (86)10 (100)8 (27)
  1. Italic signifies P < 0.05